Regulation of the human corticotropin-releasing-hormone gene promoter activity by antidepressant drugs in neuro-2A and AtT-20 cells

Neuropsychopharmacology

Volumn 29, Issue 4, 2004, Pages 785-794

  Budziszewska, Bogusława ^a   Jaworska Feil, Lucylla ^a   Tetich, Magdalena ^a   Basta Kaim, Agnieszka ^a   Kubera, Marta ^a   Leśkiewicz, Monika ^a   Lasoń, Władysław ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antidepressant drugs; AtT 20 cells; Forskolin; hCRH gene promoter activity; in vitro differentiation; Neuro 2A cells; Stable transfection

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DESIPRAMINE; FLUOXETINE; FORSKOLIN; IMIPRAMINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; REBOXETINE; TIANEPTINE; VENLAFAXINE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN; CELL STRAIN ATT 20; CELL STRAIN NEURO 2A; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; GENE ACTIVITY; GENE CONTROL; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HORMONE SYNTHESIS; HYPOPHYSIS CELL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PSYCHOPHARMACOLOGY; REPORTER GENE;

ANIMALS; ANTIDEPRESSIVE AGENTS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CORTICOTROPIN-RELEASING HORMONE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FORSKOLIN; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; MICE; MOLECULAR BIOLOGY; NEUROBLASTOMA; PITUITARY GLAND; POTASSIUM CHLORIDE; PROMOTER REGIONS (GENETICS); TETRADECANOYLPHORBOL ACETATE; TRANSFECTION;

EID: 1642529032     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300379     Document Type: Article

References (57)

1. Altamura AC, De Novellis F, Mauri MC, Gomeni R (1987). Plasma and brain pharmacokinetics of mianserin after single and multiple dosing in mice. Prog Neuropsychopharmacol Biol Psychiatry 11: 23-33.
2. Aubry JM, Pozzoli G, Vale WW (1999). Chronic treatment with the antidepressant amitriptyline decreases CRF-R1 receptor mRNA levels in the rat amygdala. Neurosci Lett 266: 197-200.
3. Bartels M, Albert K (1995). Detection of psychoactive drugs using 19F MR spectroscopy. J Neural Transm Gen Sect 99: 1-6.
4. Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ (1992). The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin- releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 572: 117-125.
5. Brady LS, Whitfield HJ, Fox RJ, Gold PW, Herkenham M (1991). Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. J Clin Invest 87: 831-837.
6. Budziszewska B, Jaworska-Feil L, Kajta M, Lasoñ W (2000). Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism. Br J Pharmacol 130: 1385-1393.
7. Budziszewska B, Jaworska-Feil L, Tetich M, Basta-Kaim A, Kubera M, Leśkiewicz M et al (2002). Effect of antidepressant drugs on the human corticotropin-releasing-hormone gene promoter activity in Neuro-2A cells. Pol J Pharmacol 54: 711-716.
8. Chatterjee D, Chakraborty M, Anderson GM (1992). Differentiation of Neuro-2a neuroblastoma cells by an antibody to GM3 ganglioside. Brain Res 583: 31-44.
9. Da̧browski S, Kur J (1998). Cloning and expression in Escherichia coli of the recombinant his-tagged DNA polymerases from Pyrococcus furiosus and Pyrococcus woesei. Protein Express Purif 14: 131-138.
10. De Girolamo LA, Billett EE, Hargreaves AJ (2000). Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on differentiating mouse N2a neuroblastoma cells. J Neurochem 75: 133-140.
11. Delbende C, Tranchand Bunel D, Tarozzo G, Grino M, Oliver C, Mocaer E et al (1994). Effect of chronic treatment with the antidepressant tianeptine on the hypothalamo-pituitary-adrenal axis. Eur J Pharmacl 251: 245-251.
12. Fadda P, Pani L, Porcella A, Fratta W (1995). Chronic imipramine, L-sulpiride and mianserin decrease corticotropin releasing factor levels in the rat brain. Neurosci Lett 192: 121-123.
13. Glotzbach RK, Preskorn SH (1982). Brain concentration of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically doses rats. Psychopharmacology 78: 25-27.
14. Groenink L, Dirks A, Verdouw PM, Schipholt M, Veening JG, van der Gugten J et al (2002). HPA axis dysregulation in mice overexpressing corticotropin releasing hormone. Biol Psychiatry 51: 875-881.
15. Guardiola-Diaz HM, Boswell C, Seasholtz AF (1994). The cAMP-responsive element in the corticotropin-releasing hormone gene mediates transcriptional regulation by depolarization. J Biol Chem 269: 14784-14791.
16. Guardiola-Diaz HM, Kolinske JS, Gates LH, Seasholtz AF (1996). Negative glucorticoid regulation of cyclic adenosine 3′,5′-monophosphate- stimulated corticotropin-releasing hormone-reporter expression in AtT-20 cells. Mol Endocrinol 10: 317-329.
17. Herman JP, Cullinan WE (1997). Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 20: 78-84.
18. Holsboer F, Gerken A, Stalla GK, Muller OA (1985). ACTH, cortisol and corticosterone output after ovine corticotrophin-releasing factor challenge during depression and after recovery. Biol Psychiat 20: 276-286.
19. Hosoda K, Duman RS (1993). Regulation of beta 1-adrenergic receptor mRNA and ligand binding by antidepressant treatments and norepinephrine depletion in rat frontal cortex. J Neurochem 60: 1335-1343.
20. Hrdina PD, Dubas TC (1981). Brain distribution and kinetics of desipramine in the rat. Can J Physiol Pharmacol 59: 163-167.
21. Itoi K, Horiba N, Tozawa F, Sakai Y, Sakai K, Abe K et al (1996). Major role of 3′,5′-cyclic adenosine monophosphate-dependent protein kinase A pathway in corticotropin-releasing factor gene expression in the rat hypothalamus in vivo. Endocrinology 137: 2389-2396.
22. Jeffcoate WJ, Silverstone JT, Edwards CRW, Besser GM (1979). Psychiatric manifestations of Cushing's Syndrome: response to lowering of plasma cortisol. Q J Med 191: 465-472.
23. Kadota Y, Niiya A, Masaki R, Yamamoto A, Araki M, Taketani S (1997). A newly identified membrane protein localized exclusively in intracellular organelles of neurons. Brain Res Mol Brain Res 46: 265-273.
24. Karson CN, Newton JE, Mohanakrishnan P, Sprigg J, Komoroski RA (1992). Fluoxetine and trifluoperazine in human brain: a 19F-nuclear magnetic resonance spectroscopy study. Psychiatry Res 45: 95-104.
25. Klebe RJ, Ruddle FH (1969). Neuroblastoma: cell culture analysis of a differentiating stem cell system. J Cell Biol 43: 69.
26. Kole MH, Swan L, Fuchs E (2002). The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats. Eur J Neurosci 16: 807-816.
27. Komoroski RA, Newton JE, Cardwell D, Sprigg J, Pearce J, Karson CN (1994). In vivo 19F spin relaxation and localized spectroscopy of fluoxetine in human brain. Magn Reson Med 31: 204-211.
28. Kornhuber J, Retz W, Riederer P (1995). Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? J Neural Transm Suppl 46: 315-323.
29. Linkowski P, Mendlewicz J, LeClerc R, Brasseur M, Hubain P, Goldstein J et al (1985). The 24-hour profile of ACTH and cortisol in major depressive illness. J Clin Endocrinol Metab 61: 429-438.
30. Malkoski SP, Dorin RI (1999). Composite glucocorticoid regulation at a functionally defined negative glucocorticoid response element of the human corticotropin-releasing hormone gene. Mol Endocrinol 13: 1629-1644.
31. Manier DH, Shelton RC, Sulser F (2002). Noradrenergic antidepressants: does chronic treatment increase or decrease nuclear CREB-P? J Neural Transm 109: 91-99.
32. Miyake K, Fukuchi H, Kitaura T, Kimura M, Sarai K, Nakahara T (1990). Pharmacokinetics of amitriptyline and its demetiylated metabolite in serum and specific brain regions of rats after acute and chronic administration of amitriptyline. J Pharmaceut Sci 79: 288-291.
33. Murphy BEP (1997). Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 22: S125-S132.
34. Nemeroff CB, Widerlov E, Bisette G, Walleus H, Karlsson I, Eklund K et al (1984). Elevated concentrations of CSF corticotropin releasing factor-like immunoreactivity in depressed patients. Science 226: 1342-1344.
35. Nestler EJ, McMahon A, Sabban EL, Tallman JF, Duman RS (1990). Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc Natl Acad Sci USA 87: 7522-7526.
36. Nibuya M, Nestler EJ, Duman RS (1996). Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16: 2365-2372.
37. O'Brien D, Skelton KH, Owens MJ, Nemeroff CB (2001). Are CRF receptor antagonists potential antidepressants? Hum Psychopharmacol 16: 81-87.
38. Okuyama-Tamura M, Mikuni M, Kojima I (2003). Modulation of the human glucocorticoid receptor function by antidepressive compounds. Neurosci Lett 342: 206-210.
39. Pariante CM, Miller AH (2001). Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49: 391-404.
40. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH (1997). Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 52: 571-581.
41. Post A, Crochemore C, Uhr M, Holsboer F, Behl C (2000). Differential induction of NF-kappaB activity and neural cell death by antidepressants in vitro. Eur J Neurosci 12: 4331-4337.
42. Raadsheer FC, Hoogendijk WJG, Stam FC, Tilders FJH, Swaab DF (1994). Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 460: 436-444.
43. Ratka A, Sutanto W, Bloemers M, De Kloet ER (1989). On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology 50: 117-123.
44. Rosen LB, Majzoub JA, Adler GK (1992). Effects of glucocorticoid on corticotropin-releasing hormone gene regulation by second messenger pathways in NPLC and AtT-20 cells. Endocrinology 130: 2237-2244.
45. Rossby SP, Manier DH, Liang S, Nalepa I, Sulser F (1999). Pharmacological actions of the antidepressant venlafaxine beyond aminergic receptors. Int J Neuropsychopharmcol 2: 1-8.
46. Schwaninger M, Schofl C, Blume R, Rossig L, Knepel W (1995). Inhibition by antidepressant drugs of cyclic AMP response element-binding protein/cyclic AMP response element-directed gene transcription. Mol Pharmacol 47: 1112-1118.
47. Seasholtz AF, Thompson RC, Douglass JO (1988). Identification of a cyclic adenosine monophosphate-responsive element in the rat corticotropin-releasing hormone gene. Mol Endocrinol 2: 1311-1319.
48. Shibahara S, Morimoto Y, Furutani Y, Notake M, Takahashi H, Shimizu S et al (1983). Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene. EMBO J 2: 775-779.
49. Skaper SD, Adelson GL, Seegmiller JE (1976). Metabolism of biogenic amines in neuroblastoma and glioma cells in culture. J Neurochem 27: 1065-1070.
50. Spengler D, Rupprecht R, Van LP, Holsboer F (1992). Identification and characterization of a 3′,5′-cyclic adenosine monophosphate- responsive element in the human corticotropin-releasing hormone gene promoter. Mol Endocrinol 6: 1931-1941.
51. Stout SC, Owens MJ, Nemeroff CB (2002). Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary- adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Ther 300: 1085-1092.
52. Tamura T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S (2002). The effects of antidepressant drug treatments on activator protein-1 binding activity in the rat brain. Prog Neuropsychopharmacol Biol Psychiatry 26: 375-381.
53. Vamvakopoulos NC, Chrousos GP (1994). Hormonal regulation of human corticotropin-releasing hormone gene expression: implications for the stress response and immune/inflammatory reaction. Endocrine Rev 15: 409-420.
54. Van LP, Spengler DH, Holsboer F (1990). Glucocorticoid repression of 3′,5′-cyclic-adenosine monophosphate-dependent human corticotropin-releasing-hormone gene promoter activity in a transfected mouse anterior pituitary cell line. Endocrinology 127: 1412-1418.
55. Watanabe Y, Gould E, Daniels DC, Cameron H, McEwen BS (1992). Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol 222: 157-162.
56. Woods MD, Shipston MJ, Mullens EL, Antoni FA (1992). Pituitary corticotrope tumor (AtT20) cells as a model system for the study of early inhibition by glucocorticoids. Endocrinology 131: 2873-2880.
57. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M et al (2000). Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34: 171-181.